Heteroannelated anthraquinone derivatives for inhibiting cancers
Methods and pharmaceutical compositions for treating cancer utilizing compounds characterized by the following structure: and their pharmaceutically acceptable salts.
1. A method for treating cancer in a mammalian subject in need thereof, consisting of:
inducing apoptosis, inhibiting cancer cell proliferation, or inhibiting telomerase activity in cancer cells of the mammalian subject by administering to the mammalian subject an effective amount of a pharmaceutical composition comprising:
a compound having the formula (I):
or pharmaceutically acceptable salts thereof; and
a pharmaceutically acceptable carrier, a diluent, an excipient, or a combination thereof.
2. The method of claim 1 , wherein the cancer is selected from the group consisting of a lung cancer, a hepatic cancer, a bladder cancer, a breast cancer, a prostate cancer, a kidney cancer, an oral cancer, a cervical cancer and an ovarian cancer.
3. A method for inducing apoptosis in a mammalian cancer cell comprising the step of:
administering to the mammalian cancer cell an effective amount of a pharmaceutical composition comprising: anthra[2,1-c][1,2,5]thiadiazole-6,11-dione, or pharmaceutically acceptable salts thereof; and a pharmaceutically acceptable carrier, a diluent, an excipient, or a combination thereof.
4. The method of claim 3 , wherein the cancer cell is selected from the group consisting of a lung cancer cell, a hepatic cancer cell, a bladder cancer cell, a breast cancer cell, a prostate cancer cell, a kidney cancer cell, an oral cancer cell, a cervical cancer cell and an ovarian cancer cell.
5. A method for inhibiting proliferation of a mammalian cancer cell, comprising the step of:
administering to the cancer cell an effective amount of a pharmaceutical composition comprising: anthra[2,1-c][1,2,5]thiadiazole-6,11-dione, or pharmaceutically acceptable salts thereof;
and a pharmaceutically acceptable carrier, a diluent, an excipient, or a combination thereof.
6. The method of claim 5 , wherein the cancer cell is one selected from the group consisting of a lung cancer cell, a hepatic cancer cell, a bladder cancer cell, a breast cancer cell, a prostate cancer cell, a kidney cancer cell, an oral cancer cell, a cervical cancer cell and an ovarian cancer cell.
7. A method for inducing apoptosis in one or more cancer cells of a mammalian subject, comprising the step of:
administering to the subject a biologically active amount of a pharmaceutical composition comprising:
anthra[2,1-c][1,2,5]thiadiazole-6,11-dione, or pharmaceutically acceptable salts thereof; and
a pharmaceutically acceptable carrier, a diluent, an excipient, or a combination thereof.
8. The method of claim 7 , wherein the one or more cells are selected from the group consisting of lung cancer cells, hepatic cancer cells, bladder cancer cells, breast cancer cells, colon cancer cells, pancreatic cancer cells, prostate cancer cells, kidney cancer cells, oral cancer cells, cervical cancer cells and ovarian cancer cells.
9. A method for inhibiting cancer cell proliferation in a mammalian subject comprising the step of:
administering to one or more cancer cells in the subject a biologically active amount of a pharmaceutical composition comprising:
anthra[2,1-c][1,2,5]thiadiazole-6,11-dione, or pharmaceutically acceptable salts thereof; and
a pharmaceutically acceptable carrier, a diluent, an excipient, or a combination thereof.
10. The method of claim 9 , wherein the one or more cells are selected from the group consisting of lung cancer cells, hepatic cancer cells, bladder cancer cells, breast cancer cells, colon cancer cells, pancreatic cancer cells, prostate cancer cells, kidney cancer cells, oral cancer cells, cervical cancer cells and ovarian cancer cells.
11. A method for inhibiting a telomerase enzyme's enzymatic activity in a mammalian subject, said method comprising the step of:
exposing the telomerase of said mammalian subject to a biologically active amount of a pharmaceutical composition comprising:
anthra[2,1-c][1,2,5]thiadiazole-6,11-dione, or pharmaceutically acceptable salts thereof; and
a pharmaceutically acceptable carrier, a diluent, an excipient, or a combination thereof.